Form 4: Neumora Therapeutics President Joshua Pinto Reports Stock Option Repricing

Joshua Pinto, President of Neumora Therapeutics, reports the repricing and grant of stock options, subject to stockholder approval, according to a Form 4 filing.

Summary

• Joshua Pinto, President of Neumora Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the repricing of several stock options held by Pinto, subject to stockholder approval.
• The repricing sets the exercise price for these options at $1.69 per share.
• Pinto was also granted 3,000,000 new stock options with an exercise price of $1.69, vesting over four years from February 13, 2025.
• The repricing is contingent on Pinto remaining in service to the Issuer through August 13, 2026.
• The original exercise prices of the repriced options ranged from $2.51 to $18.07.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports factual information about stock option repricing and grants. The impact on the company's future performance is uncertain and depends on various factors.

Positives

• The repricing of stock options at a lower exercise price of $1.69 may incentivize Pinto to improve company performance.
• The grant of 3,000,000 new stock options further aligns Pinto's interests with those of the shareholders.
• The vesting schedules of the options encourage long-term commitment from Pinto.

Negatives

• The repricing of options could be viewed negatively by shareholders if it's perceived as rewarding past underperformance.
• The repricing is contingent on stockholder approval, which introduces uncertainty.
• The repricing is contingent on Pinto remaining in service to the Issuer through August 13, 2026.

Risks

• Failure to obtain stockholder approval for the option repricing would void the changes.
• The value of the options is dependent on the future stock price of Neumora Therapeutics.
• If Pinto leaves the company before August 13, 2026, the repricing may not be fully realized.

Future Outlook

The repricing is subject to stockholder approval and Pinto's continued service through August 13, 2026.

Industry Context

Option repricing is a common practice in the pharmaceutical industry to retain and incentivize key executives, especially in companies with volatile stock prices or those undergoing significant transitions.

Comparison to Industry Standards

• Comparing Neumora's executive compensation structure to similar biotech companies like Sage Therapeutics or Biogen would provide context on whether the option grants and repricing are in line with industry norms.
• Analyzing the vesting schedules and performance-based conditions of these options against industry benchmarks would further assess their competitiveness and effectiveness in incentivizing long-term value creation.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution of their ownership if the options are exercised.
• Employees may be affected by the repricing if they also hold similar options.
• The repricing aims to incentivize management, which could ultimately benefit all stakeholders if it leads to improved company performance.

Next Steps

• Neumora Therapeutics needs to obtain stockholder approval for the option repricing.
• Pinto must remain in service to the Issuer through August 13, 2026, for the repricing to remain valid.

Key Dates